THE GLAUCOMA FOUNDATION INC

1) genetic predisposition and ophthalmic outcomes; 2) optic nerve regeneration; 3) using artificial intelligence to reveal blood pressure's role in glaucoma progression; 4) ee-purposing an "old" drug for a new indication: elucidating the peripheral and central effects of glucagon-like peptide 1 receptor agonists to treat glaucoma; 5) search for functional loxl1 risk alleles with bit-starr; 6) vascular genotype-phenotype association in primary open-angle glaucoma; 7) investigating the role of impaired mitochondrial dynamics in exfoliation glaucoma; 8) uncovering the potential of pericytes as therapeutic targets for glaucoma; 9) nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial.